# Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

> **NCT00753649** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 224 (actual)

## Conditions studied

- Hepatitis B
- Tetanus
- Poliomyelitis
- Diphtheria
- Haemophilus Influenzae Type b
- Acellular Pertussis

## Interventions

- **BIOLOGICAL:** Infanrix™ hexa

## Key facts

- **NCT ID:** NCT00753649
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-23
- **Primary completion:** 2013-03-12
- **Final completion:** 2013-03-12
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753649, "Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00753649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*